Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
138.02B
Market cap138.02B
Price-Earnings ratio
18.59
Price-Earnings ratio18.59
Dividend yield
7.09%
Dividend yield7.09%
Average volume
49.81M
Average volume49.81M
High today
$24.41
High today$24.41
Low today
$24.10
Low today$24.10
Open price
$24.33
Open price$24.33
Volume
9.68M
Volume9.68M
52 Week high
$28.75
52 Week high$28.75
52 Week low
$23.11
52 Week low$23.11

Stock Snapshot

With a market cap of 138.02B, Pfizer(PFE) trades at $24.22. The stock has a price-to-earnings ratio of 18.59 and currently yields dividends of 7.09%.

During the trading session on 2026-07-10, Pfizer(PFE) shares reached a daily high of $24.41 and a low of $24.10. At a current price of $24.22, the stock is +0.5% higher than the low and still -0.8% under the high.

Trading volume for Pfizer(PFE) stock has reached 9.68M, versus its average volume of 49.81M.

The stock's 52-week range extends from a low of $23.11 to a high of $28.75.

The stock's 52-week range extends from a low of $23.11 to a high of $28.75.

PFE News

24/7 Wall St. 3h
McDonald's or Pfizer: One Offers Real Growth, One Just Pays You to Wait

McDonald’s or Pfizer: One Offers Real Growth, One Just Pays You to Wait By Trey Thoelcke Published Jul 10, 8:40AM EDT Quick Read MCD and PFE have each slipped...

McDonald's or Pfizer: One Offers Real Growth, One Just Pays You to Wait
TipRanks 5h
Pfizer price target lowered to $26 from $27 at BofA

BofA lowered the firm’s price target on Pfizer (PFE) to $26 from $27 and keeps a Neutral rating on the shares. Second quarter results are expected to highlight...

Bloomberg 6h
Pfizer Vaccine Dispute Hits Polish, Romania Air Traffic Agencies - Bloomberg.com

...

Pfizer Vaccine Dispute Hits Polish, Romania Air Traffic Agencies - Bloomberg.com

Analyst ratings

62%

of 29 ratings
Buy
31%
Hold
62.1%
Sell
6.9%

More PFE News

Simply Wall St 16h
Pfizer Stock Leads 3 AI Healthcare Picks Worth A Closer Look

Transformative AI in healthcare sits at the crossroads of powerful themes investors are watching today: pressure to improve efficiency, closer scrutiny on costs...

Pfizer Stock Leads 3 AI Healthcare Picks Worth A Closer Look
TipRanks 21h
Appeals court upholds win for AstraZeneca in Pfizer patent fight, Reuters says

A U.S. appeals court on Thursday upheld a ruling for AstraZeneca (AZN) against allegations that its blockbuster lung-cancer drug Tagrisso infringed patents owne...

TipRanks 23h
Pfizer Advances RSV Vaccine Strategy With New Phase 3 Trial in India

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more c...

TipRanks 23h
Pfizer’s MUST Study Offers Fresh Insight Into Tough‑to‑Treat Multiple Myeloma

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more c...

24/7 Wall St. 23h
'It Kills Me to Say That': Cramer Won't Recommend Pfizer, Even With Its 7% Dividend

‘It Kills Me to Say That’: Cramer Won’t Recommend Pfizer, Even With Its 7% Dividend By Danielle Liverance Published Jul 9, 12:25PM EDT Quick Read Cramer passe...

'It Kills Me to Say That': Cramer Won't Recommend Pfizer, Even With Its 7% Dividend
Simply Wall St 2d
Pfizer On IBRANCE Approval And Dividend Move Has Valuation Back In Focus

Advertisement FDA approval and dividend move put Pfizer in focus Pfizer (PFE) has drawn fresh attention after the FDA approved a new maintenance use for IBRAN...

Pfizer On IBRANCE Approval And Dividend Move Has Valuation Back In Focus
Barron's 3d
Former Pfizer Building Is Crumbling—Just as the Stock Has

Biotech and Pharma Former Pfizer Building Is Crumbling—Just as the Stock Has In this article PFE SPX LLY BNTX Workers at the former Pfizer headquarters were eva...

Former Pfizer Building Is Crumbling—Just as the Stock Has

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.